Stopping Ozempic may be bad for your health
In people with type 2 diabetes (T2D) and no established cardiovascular disease (CVD), starting glucagon-like peptide-1 receptor agonist (GLP-1) treatment and then stopping is associated with twice the combined risk of heart attack, stroke or death compared with staying on treatment, according to a study published in The Lancet Regional Health—Europe.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
